海普瑞(09989)：ENOPARIN获得阿根廷批准

智通财经2025-02-26

智通财经APP讯，海普瑞(09989)发布公告，旗下全资附属公司深圳市天道医药有限公司生产的Enoparin(集团依诺肝素钠注射液领先药物之一)已获得阿根廷国家药品、食品和医疗器械管理局(ANMAT)批准上市销售。本次获批，代表集团海普瑞的依诺肝素钠制剂将会于阿根廷市场进行销售，将进一步提升集团依诺肝素钠制剂在全球的市场占有率。公司认为本次核准是集团制剂业务实施国际化布局的另一个重要成果，再次证明...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2514838336?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-02-26 18:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514838336","market":"us","top_or_hot":-1,"title":"海普瑞(09989)：ENOPARIN获得阿根廷批准","media":"智通财经","content":"<div>\n<p>智通财经APP讯，海普瑞(09989)发布公告，旗下全资附属公司深圳市天道医药有限公司生产的Enoparin(集团依诺肝素钠注射液领先药物之一)已获得阿根廷国家药品、食品和医疗器械管理局(ANMAT)批准上市销售。本次获批，代表集团海普瑞的依诺肝素钠制剂将会于阿根廷市场进行销售，将进一步提升集团依诺肝素钠制剂在全球的市场占有率。公司认为本次核准是集团制剂业务实施国际化布局的另一个重要成果，再次证明...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1254812.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>海普瑞(09989)：ENOPARIN获得阿根廷批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n海普瑞(09989)：ENOPARIN获得阿根廷批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-02-26 18:50 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1254812.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，海普瑞(09989)发布公告，旗下全资附属公司深圳市天道医药有限公司生产的Enoparin(集团依诺肝素钠注射液领先药物之一)已获得阿根廷国家药品、食品和医疗器械管理局(ANMAT)批准上市销售。本次获批，代表集团海普瑞的依诺肝素钠制剂将会于阿根廷市场进行销售，将进一步提升集团依诺肝素钠制剂在全球的市场占有率。公司认为本次核准是集团制剂业务实施国际化布局的另一个重要成果，再次证明...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1254812.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09989","symbol_name":"海普瑞","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1254812.html","article_id":"2514838336","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514838336","pubTimestamp":1740567032,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，海普瑞(09989)发布公告，旗下全资附属公司深圳市天道医药有限公司生产的Enoparin(集团依诺肝素钠注射液领先药物之一)已获得阿根廷国家药品、食品和医疗器械管理局(ANMAT)批准上市销售。本次获批，代表集团海普瑞的依诺肝素钠制剂将会于阿根廷市场进行销售，将进一步提升集团依诺肝素钠制剂在全球的市场占有率。公司认为本次核准是集团制剂业务实施国际化布局的另一个重要成果，再次证明集团进军海外市场的能力。未来，集团将会持续发力，加速集团拓展全球市场的进程及销售通路建设，为后续进一步加强海外市场发展做好铺垫。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"09989":"海普瑞","BK0188":"融资融券","002399":"海普瑞","BK1191":"制药","BK0070":"员工持股","BK0239":"医药制造"},"translate_title":"Hepalink (09989): ENOPARIN Gets Approval in Argentina","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09989":1,"002399":1},"content_text":"智通财经APP讯，海普瑞(09989)发布公告，旗下全资附属公司深圳市天道医药有限公司生产的Enoparin(集团依诺肝素钠注射液领先药物之一)已获得阿根廷国家药品、食品和医疗器械管理局(ANMAT)批准上市销售。本次获批，代表集团海普瑞的依诺肝素钠制剂将会于阿根廷市场进行销售，将进一步提升集团依诺肝素钠制剂在全球的市场占有率。公司认为本次核准是集团制剂业务实施国际化布局的另一个重要成果，再次证明集团进军海外市场的能力。未来，集团将会持续发力，加速集团拓展全球市场的进程及销售通路建设，为后续进一步加强海外市场发展做好铺垫。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2514838336","isCrawlerRequest":true}